|Current questions for the treatment of advanced gastric cancer|
A Cervantes, D Roda, N Tarazona, S Rosello, JA Perez-Fidalgo
Cancer treatment reviews 39 (1), 60-67, 2013
|Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients|
I Chirivella, B Bermejo, A Insa, A Pérez-Fidalgo, A Magro, S Rosello, ...
Breast cancer research and treatment 114 (3), 479-484, 2009
|Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors|
A Cervantes, E Elez, D Roda, J Ecsedy, T Macarulla, K Venkatakrishnan, ...
Clinical cancer research 18 (17), 4764-4774, 2012
|Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study|
J Tabernero, A Cervantes, F Rivera, E Martinelli, F Rojo, ...
Journal of clinical oncology 28 (7), 1181-1189, 2010
|Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer|
M Frasson, E Garcia‐Granero, D Roda, B Flor‐Lorente, S Roselló, ...
Cancer 117 (14), 3118-3125, 2011
|A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid …|
F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ...
Clinical Cancer Research 17 (19), 6304-6312, 2011
|A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors|
C Saura, D Roda, S Roselló, M Oliveira, T Macarulla, JA Pérez-Fidalgo, ...
Cancer discovery 7 (1), 102-113, 2017
|Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study|
J Tabernero, F Ciardiello, F Rivera, E Rodriguez-Braun, FJ Ramos, ...
Annals of oncology 21 (7), 1537-1545, 2010
|The treatment of advanced gastric cancer: current strategies and future perspectives|
A Cervantes, S Roselló, D Roda, E Rodriguez-Braun
Annals of oncology 19, v103-v107, 2008
|Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics|
T Macarulla, A Cervantes, E Elez, E Rodríguez-Braun, J Baselga, ...
Molecular cancer therapeutics 9 (10), 2844-2852, 2010
|Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens|
JA Pérez-Fidalgo, S Roselló, E García-Garré, E Jordá, P Martín-Martorell, ...
Breast cancer research and treatment 120 (1), 245-251, 2010
|Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution …|
P Martin-Martorell, S Rosello, E Rodriguez-Braun, I Chirivella, A Bosch, ...
British journal of cancer 99 (3), 455-458, 2008
|Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer|
R Dienstmann, A Patnaik, R Garcia-Carbonero, A Cervantes, M Benavent, ...
Cancer discovery 5 (6), 598-609, 2015
|Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer|
F Sclafani, G Brown, D Cunningham, A Wotherspoon, LST Mendes, ...
British journal of cancer 117 (10), 1478-1485, 2017
|Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer|
N Tarazona, F Gimeno-Valiente, V Gambardella, S Zuñiga, ...
Annals of Oncology 30 (11), 1804-1812, 2019
|A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients …|
F Atzori, J Tabernero, A Cervantes, M Botero, K Hsu, H Brown, W Hanley, ...
Journal of Clinical Oncology 26 (15_suppl), 3519-3519, 2008
|Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines|
S Roselló, I Blasco, LG Fabregat, A Cervantes, K Jordan
Annals of Oncology 28, iv100-iv118, 2017
|Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase|
A Chakravarty, V Shinde, J Tabernero, A Cervantes, RB Cohen, EC Dees, ...
Cancer research 71 (3), 675-685, 2011
|Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system|
JAP Fidalgo, D Roda, S Roselló, E Rodríguez-Braun, A Cervantes
Clinical and Translational Oncology 11 (12), 787-798, 2009
|RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial|
F Sclafani, D Gonzalez, D Cunningham, SH Wilson, C Peckitt, J Giralt, ...
European Journal of Cancer 50 (8), 1430-1436, 2014